Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 159   

Articles published

GSK 1,332.50 -0.50 (-0.04%)
price chart
How Safe Are GlaxoSmithKline plc & Royal Dutch Shell Plc's 6%+ Dividend Yields?
Two of the FTSE 100's dividend stalwarts, GlaxoSmithKline (LSE: GSK) and Royal Dutch Shell (LSE: RDSB), have both recently hit multi-year lows on concerns that neither company will be able to afford its dividend payout this year.
3 More Shares For The Week Ahead: GlaxoSmithKline plc, ITV plc And British ...
As an example of that, GlaxoSmithKline (LSE: GSK)(NYSE: GSK.US) has just received regulatory approval for the world's first malaria vaccine - it's only aimed at babies in Africa at the moment and Glaxo will not be making a profit with it, but it's a ...
Which is Your Best Pharma Bet: GlaxoSmithKline plc, AstraZeneca plc Or Shire ...  Yahoo Finance UK
GlaxoSmithKline plc (GSK) – Investment Analysts' Recent Ratings Changes ...
7/23/2015 - GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at AlphaValue. They now have a GBX 1,732 ($26.88) price target on the stock.
GlaxoSmithKline plc Stock Rating Reaffirmed by AlphaValue (GSK)  The Legacy
AlphaValue Reiterates “Buy” Rating for GlaxoSmithKline plc (GSK) - Watch ...  Watch List News
Is This A Contrarian Buy Signal For GlaxoSmithKline plc?
Glaxo has also underperformed the FTSE 100 over the last five years, climbing 14% versus 26% for the blue-chip index. However, every cloud has a silver lining.
Morningstar Issues “A+” Credit Rating to GlaxoSmithKline plc (GSK) - Dakota ...
GlaxoSmithKline plc logo GlaxoSmithKline plc (NYSE:GSK) has earned an “A+” credit rating from analysts at Morningstar.
GlaxoSmithKline plc Receives $47.00 Consensus Price Target from Analysts ...  The Legacy
Company Shares of GlaxoSmithKline PLC Drops by -3.65% | Insider Trading Report  Insider Trading Report
Why GlaxoSmithKline plc And Vertu Motors Plc Look Like Star Buys
For example, GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) remains a relatively unpopular stock among investors. Evidence of this can be seen in the company's share price performance, with GlaxoSmithKline's valuation having fallen by 11% in the last year ...
Fundamental Analysis: GlaxoSmithKline PLC (NYSE:GSK)  Stock Markets Daily
GlaxoSmithKline plc Price Target Lowered to $42.00 at Sanford C. Bernstein (GSK)  Dakota Financial News
Why GlaxoSmithKline plc Is Worth More Than 1700p Per Share
GlaxoSmithKline (LSE: GSK) is one of the most undervalued and underappreciated FTSE 100 companies, in my opinion. Glaxo is also difficult to understand. On the face of it, many investors see the company as one of the UK's largest pharmaceutical ...
How Safe Is GlaxoSmithKline plc's 6% Dividend Yield?
At present, the company's shares yield just under 6%, around double the market average, making them extremely attractive in the current interest rate environment.
Is It Time To Sell AstraZeneca plc And Buy GlaxoSmithKline plc?
So the heyday of the pharmaceutical industry is over. Many blockbuster drugs have tumbled over the patent cliff, and there are now a range of 'me-too' drugs which produce a fraction of the revenues of the big drugs of yesteryear.
4 Shares Yielding More Than 5%: GlaxoSmithKline plc, SSE plc, Infinis Energy ...
GlaxoSmithKline (LSE: GSK) is struggling with the increase in generic competition, as its major blockbuster drugs lose patent protection.